Gábor Rubovszky

8PUBLICATIONS
46CO-AUTHORS
Major global burdens of diseasePredictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 15, 2026
Cancer Diagnoses and Deaths in Hungary, 2011-2023: Nationwide Trends Before, During, and After the COVID-19 Pandemic.

|Dec 05, 2025
The Neutrophil-to-Lymphocyte Ratio May be the Best Serological Biomarker in Predicting Longer Survival in Neoadjuvant Treatment of Triple-Negative Breast Cancer.

Gábor Rubovszky, Norbert Mészáros, Zoltán Mátrai

|Nov 09, 2024
Glucocorticoid Receptor Isoforms in Breast Cancer Raise Implications for Personalised Supportive Therapies.

Henriett Butz, Viktória Vereczki, Barna Budai

|Sep 14, 2024
How to Tackle Discordance in Adjuvant Chemotherapy Recommendations by Using Oncotype DX Results, in Early-Stage Breast Cancer.

Katalin Boér, Ambrus Kaposi, Judit Kocsis

|Aug 09, 2024
The role of everolimus in metastatic breast cancer and possibilities of moving forward-a narrative review.

Gabor Rubovszky

|Jun 30, 2023
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.

Aditya Bardia, Komal Jhaveri, Kevin Kalinsky

Pageof 2

Frequent Collaborators

1 joint publications

Michael Gnant

1 joint publications

Amylou C Dueck

1 joint publications

Miguel Martin

1 joint publications

Richard Greil